Head-To-Head Contrast: EOM Pharmaceutical (OTCMKTS:IMUC) and Siga Technologies (NASDAQ:SIGA)

Siga Technologies (NASDAQ:SIGA) and EOM Pharmaceutical (OTCMKTS:IMUC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Earnings and Valuation

This table compares Siga Technologies and EOM Pharmaceutical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57 million	3.79	$23.28 million	$0.31	16.13
EOM Pharmaceutical	N/A	N/A	-$1.89 million	N/A	N/A

Siga Technologies has higher revenue and earnings than EOM Pharmaceutical.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Siga Technologies and EOM Pharmaceutical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	0	1	0	0	2.00
EOM Pharmaceutical	0	0	0	0	0.00

Insider & Institutional Ownership

55.4% of Siga Technologies shares are held by institutional investors. 2.0% of Siga Technologies shares are held by insiders. Comparatively, 3.3% of EOM Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Siga Technologies and EOM Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Siga Technologies	24.61%	11.25%	9.98%
EOM Pharmaceutical	N/A	N/A	N/A

Volatility & Risk

Siga Technologies has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, EOM Pharmaceutical has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Summary

Siga Technologies beats EOM Pharmaceutical on 8 of the 9 factors compared between the two stocks.

About Siga Technologies

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

About EOM Pharmaceutical

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.